PYXS News
Archived Headlines
- Tumor biotech Pyxis Oncology sets terms for $125 million IPO 10/04/21
- US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week 09/17/21
- US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week 09/17/21
- US IPO Weekly Recap: The Fall IPO market is in full swing with an 11 IPO week 09/17/21
- Tumor biotech Pyxis Oncology files for a $100 million IPO 09/17/21
See more
US IPO Weekly Recap: Healthcare and Canadian crosslistings lead an 8 IPO week
Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma...read more
Tumor biotech Pyxis Oncology prices further upsized IPO at $16 high end
Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, raised $168 million by offering 10.5 million shares at $16, the high end of the range of $14 to $16. The company offered 1.0 million more shares than...read more
Tumor biotech Pyxis Oncology ups share offering by 14% ahead of $143 million IPO
Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $143 million by offering 9.5 million shares...read more
Tumor biotech Pyxis Oncology sets terms for $125 million IPO
Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to...read more